Forian Inc (FORA)

$2.35

+0.01

(+0.43%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $2.33
    $2.35
    $2.35
    downward going graph

    0.85%

    Downside

    Day's Volatility :0.85%

    Upside

    0.0%

    downward going graph
  • $1.85
    $4.15
    $2.35
    downward going graph

    21.45%

    Downside

    52 Weeks Volatility :55.52%

    Upside

    43.37%

    downward going graph

Returns

PeriodForian IncSector (Health Care)Index (Russel 2000)
3 Months
-15.16%
5.1%
0.0%
6 Months
-15.77%
4.9%
0.0%
1 Year
-1.26%
16.6%
0.0%
3 Years
-77.77%
13.2%
-22.3%

Highlights

Market Capitalization
73.1M
Book Value
$0.82
Earnings Per Share (EPS)
0.03
PE Ratio
78.33
PEG Ratio
0.98
Wall Street Target Price
5.0
Profit Margin
9.65%
Operating Margin TTM
-42.46%
Return On Assets TTM
-6.32%
Return On Equity TTM
5.63%
Revenue TTM
20.4M
Revenue Per Share TTM
0.65
Quarterly Revenue Growth YOY
-2.4%
Gross Profit TTM
21.1M
EBITDA
-5.7M
Diluted Eps TTM
0.03
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.18
EPS Estimate Next Year
-0.12
EPS Estimate Current Quarter
-0.02
EPS Estimate Next Quarter
-0.01

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Forian Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 112.77%

Current $2.35
Target $5.00

Company Financials

FY20Y/Y Change
Revenue
544.9K
-
Net Income
-5.0M
↑ 286.13%
Net Profit Margin
-913.36%
-
FY21Y/Y Change
Revenue
16.9M
↑ 2997.93%
Net Income
-26.6M
↑ 433.52%
Net Profit Margin
-157.3%
↑ 756.06%
FY22Y/Y Change
Revenue
28.0M
↑ 65.91%
Net Income
-26.0M
↓ 2.18%
Net Profit Margin
-92.74%
↑ 64.56%
FY23Y/Y Change
Revenue
20.5M
↓ 26.87%
Net Income
-425.2K
↓ 98.36%
Net Profit Margin
-2.08%
↑ 90.66%
Q1 FY23Q/Q Change
Revenue
4.9M
↓ 38.38%
Net Income
-2.2M
↓ 36.77%
Net Profit Margin
-46.17%
↓ 1.17%
Q2 FY23Q/Q Change
Revenue
4.9M
↑ 0.48%
Net Income
-1.1M
↓ 50.07%
Net Profit Margin
-22.95%
↑ 23.22%
Q3 FY23Q/Q Change
Revenue
5.3M
↑ 9.3%
Net Income
4.3M
↓ 486.71%
Net Profit Margin
81.18%
↑ 104.13%
Q4 FY23Q/Q Change
Revenue
5.4M
↑ 0.38%
Net Income
1.4M
↓ 68.01%
Net Profit Margin
25.87%
↓ 55.31%
Q1 FY24Q/Q Change
Revenue
4.9M
↓ 9.16%
Net Income
-1.2M
↓ 187.3%
Net Profit Margin
-24.86%
↓ 50.73%
Q2 FY24Q/Q Change
Revenue
4.8M
↓ 2.06%
Net Income
-2.6M
↑ 110.56%
Net Profit Margin
-53.45%
↓ 28.59%
FY19Y/Y Change
Total Assets
179.0K
-
Total Liabilities
460.1K
-
FY20Y/Y Change
Total Assets
12.6M
↑ 6911.84%
Total Liabilities
1.3M
↑ 179.79%
FY21Y/Y Change
Total Assets
56.8M
↑ 352.77%
Total Liabilities
31.7M
↑ 2360.41%
FY22Y/Y Change
Total Assets
46.3M
↓ 18.62%
Total Liabilities
33.8M
↑ 6.83%
FY23Y/Y Change
Total Assets
59.4M
↑ 28.36%
Total Liabilities
33.2M
↓ 1.89%
Q1 FY23Q/Q Change
Total Assets
55.6M
↑ 20.27%
Total Liabilities
35.2M
↑ 4.11%
Q2 FY23Q/Q Change
Total Assets
55.3M
↓ 0.51%
Total Liabilities
34.6M
↓ 1.9%
Q3 FY23Q/Q Change
Total Assets
58.8M
↑ 6.22%
Total Liabilities
32.1M
↓ 7.03%
Q4 FY23Q/Q Change
Total Assets
59.4M
↑ 0.99%
Total Liabilities
33.2M
↑ 3.33%
Q1 FY24Q/Q Change
Total Assets
57.5M
↓ 3.17%
Total Liabilities
31.0M
↓ 6.77%
Q2 FY24Q/Q Change
Total Assets
58.4M
↑ 1.52%
Total Liabilities
32.7M
↑ 5.77%
FY19Y/Y Change
Operating Cash Flow
-1.0M
-
Investing Cash Flow
-227.2K
-
Financing Cash Flow
1.2M
-
FY20Y/Y Change
Operating Cash Flow
-4.3M
↑ 311.74%
Investing Cash Flow
-11.4M
↑ 4918.69%
Financing Cash Flow
16.3M
↑ 1277.67%
FY21Y/Y Change
Operating Cash Flow
-17.3M
↑ 305.99%
Investing Cash Flow
-1.0M
↓ 91.01%
Financing Cash Flow
36.3M
↑ 122.37%
FY22Y/Y Change
Operating Cash Flow
-8.8M
↓ 49.15%
Investing Cash Flow
-6.5M
↑ 530.25%
Financing Cash Flow
-100.5K
↓ 100.28%
Q1 FY23Q/Q Change
Operating Cash Flow
-1.2M
↓ 664.26%
Investing Cash Flow
-633.0K
↓ 140.94%
Financing Cash Flow
-94.6K
↑ 222.63%
Q2 FY23Q/Q Change
Operating Cash Flow
-248.8K
↓ 79.75%
Investing Cash Flow
2.3M
↓ 470.34%
Financing Cash Flow
-32.8K
↓ 65.37%

Technicals Summary

Sell

Neutral

Buy

Forian Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Forian Inc
Forian Inc
-4.84%
-15.77%
-1.26%
-77.77%
-89.74%
Solventum Corp
Solventum Corp
18.43%
-4.2%
-4.2%
-4.2%
-4.2%
Doximity, Inc.
Doximity, Inc.
42.51%
26.66%
54.18%
-63.01%
-31.43%
Veeva Systems Inc.
Veeva Systems Inc.
18.46%
-6.2%
-2.75%
-30.3%
49.39%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
7.25%
-8.17%
29.12%
40.67%
40.67%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Forian Inc
Forian Inc
78.33
78.33
0.98
-0.18
0.06
-0.06
NA
0.82
Solventum Corp
Solventum Corp
NA
NA
NA
6.26
0.17
0.08
NA
NA
Doximity, Inc.
Doximity, Inc.
45.43
45.43
2.42
0.9
0.17
0.11
NA
4.92
Veeva Systems Inc.
Veeva Systems Inc.
57.42
57.42
1.39
4.76
0.13
0.06
NA
32.04
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
25.23
25.23
2.26
4.24
0.21
0.06
0.0
17.08
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Forian Inc
Forian Inc
Buy
$73.1M
-89.74%
78.33
9.65%
Solventum Corp
Solventum Corp
Hold
$10.8B
-4.2%
NA
15.73%
Doximity, Inc.
Doximity, Inc.
Hold
$6.7B
-31.43%
45.43
32.53%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$35.0B
49.39%
57.42
23.91%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$39.9B
40.67%
25.23
8.1%

Insights on Forian Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 5.36M → 4.77M (in $), with an average decrease of 5.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, 4.34M → -2.55M (in $), with an average decrease of 122.0% per quarter

  • Vs DOCS

    In the last 1 year, Doximity, Inc. has given 54.2% return, outperforming this stock by 55.5%

  • Vs VEEV

    In the last 3 years, Forian Inc has experienced a drawdown of -77.8%, however Veeva Systems Inc. resisted the overall trend and outperformed by 14.8%

Institutional Holdings

  • Oracle Investment Management Inc

    4.36%

  • Staley Capital Advisers Inc

    3.54%

  • Vanguard Group Inc

    2.49%

  • Elser Financial Planning, Inc

    2.29%

  • Canton Hathaway, LLC

    0.85%

  • Geode Capital Management, LLC

    0.53%

Company Information

forian provides a unique suite of saas solutions, data management capabilities and proprietary data and analytics to optimize and measure operational, clinical and financial performance for customers within the traditional and emerging life sciences, healthcare payer and provider segments, as well as cannabis dispensaries, manufacturers, cultivators and regulators.

Organization
Forian Inc
Employees
36
CEO
Mr. Max C. Wygod
Industry
Technology

Discover More

FAQs